Company Filing History:
Years Active: 2025
Title: Karina Winterling: Innovator in Therapeutic Proteins
Introduction
Karina Winterling is a prominent inventor based in Darmstadt, Germany. She has made significant contributions to the field of therapeutic proteins, particularly in the development of recombinant coagulation factors. Her innovative work aims to improve treatment options for patients with Hemophilia A.
Latest Patents
Karina Winterling holds a patent for a de-immunized factor VIII molecule and pharmaceutical compositions comprising the same. This invention relates to recombinant coagulation factors and provides a recombinant Factor VIII (FVIII) protein with specific point mutations that reduce immunogenicity while retaining coagulant activity. The invention also includes nucleic acids encoding the de-immunized protein, cell lines, and methods for recombinant preparation. These advancements are particularly beneficial for treating patients with Hemophilia A, including those who have developed an immune response to FVIII.
Career Highlights
Karina Winterling is associated with Biotest AG, where she continues to advance her research in therapeutic proteins. Her work has the potential to offer safe alternatives for patients who have not yet been treated with FVIII products, as well as for those undergoing immune-tolerance-induction therapy.
Collaborations
Karina collaborates with notable colleagues such as Steffen Kistner and Jens Daufenbach, contributing to a dynamic research environment focused on innovative solutions in the field of coagulation factors.
Conclusion
Karina Winterling's contributions to the field of therapeutic proteins exemplify the impact of innovation in medicine. Her work not only enhances treatment options for patients with Hemophilia A but also showcases the importance of collaboration in scientific research.